Replagal Enzyme Replacement Therapy for Adults With Fabry Disease

NCT00097890 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Replagal (Agalsidase Alfa)
DRUG: Replagal

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)